What is NDC 68180-151?

68180-151 is the product NDC for Mirabegron, Mirabegron 25 mg/1 tablet, film coated, extended release, listed with the FDA by Lupin Pharmaceuticals, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Lupin Pharmaceuticals, Inc., NDC labeler code 68180. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Mirabegron?

16 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Mirabegron NDC 68180-151 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)68180-151Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68180-0151Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68180-151-06	68180015106	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68180-151-06)Marketed from Apr 19, 2024
68180-151-09	68180015109	90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68180-151-09)Marketed from Apr 19, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mirabegron
Generic name (nonproprietary): mirabegron
Active ingredients: Mirabegron — 25 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.NDC labeler code 68180
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209485
Marketing start: Apr 19, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic beta3-Agonists (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 68180-151_b26f08e4-dfe4-4a0f-b6b5-e9abb495e415SPL ID b26f08e4-dfe4-4a0f-b6b5-e9abb495e415SPL set ID d22d3d12-8466-46db-bc19-d13e87c6115cRxCUI 1300791, 1300801UNII MVR3JL3B2VUPC 0368180152064, 0368180151067
Pharmacologic class: beta3-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468180015106 followed by a unit qualifier and the quantity

Package 68180-0151-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 24, 2025.

Indications (excerpt from the label)

Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Extended-Release Tablets Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Pediatric use information is approved for Astellas Pharma Global Development, Inc.'s MYRBETRIQ (mirabegron extended-release tablets). However, due to Astellas Pharma Global Development, Inc.'s marketing exclusivity rights, …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 68180-151

What is NDC 68180-151?: 68180-151 is the product NDC for Mirabegron, Mirabegron 25 mg/1 tablet, film coated, extended release, listed with the FDA by Lupin Pharmaceuticals, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Mirabegron.
What is the active ingredient?: Mirabegron.
Who is the labeler?: Lupin Pharmaceuticals, Inc., NDC labeler code 68180. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Mirabegron?: 16 other product NDCs are listed under this name. See all Mirabegron NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Mirabegron NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Mirabegron	Mirabegron 8 mg/mL	For suspension, Extended releaseOral	Ascend Laboratories, LLC	67877-890	67877-0890-88
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	REMEDYREPACK INC.	70518-4665	70518-4665-00
Mirabegron	Mirabegron 25 mg/1	Tablet, Extended releaseOral	REMEDYREPACK INC.	70518-4631	70518-4631-00
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Amneal Pharmaceuticals NY LLC	69238-2861	69238-2861-0169238-2861-02
Mirabegron	Mirabegron 25 mg/1	Tablet, Film coated, Extended releaseOral	Amneal Pharmaceuticals NY LLC	69238-2860	69238-2860-0169238-2860-02
Mirabegron	Mirabegron 25 mg/1	Tablet, Film coated, Extended releaseOral	Qilu Pharmaceutical Co., Ltd.	67184-0571	67184-0571-0167184-0571-02
Mirabegron	Mirabegron 50 mg/1	Tablet, Extended releaseOral	REMEDYREPACK INC.	70518-4304	70518-4304-00
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Lupin Pharmaceuticals, Inc.	68180-152	68180-0152-0668180-0152-09
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2808	71335-2808-01
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2810	71335-2810-01

All 17 Mirabegron NDCs

Other NDCs under ANDA 209485

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209485
Product	Strength	Form · route	Labeler	Product NDC
Mirabegron	Mirabegron 25 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2807
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2808
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2810
Mirabegron	Mirabegron 25 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2809
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	REMEDYREPACK INC.	70518-4665
Mirabegron	Mirabegron 50 mg/1	Tablet, Film coated, Extended releaseOral	Lupin Pharmaceuticals, Inc.	68180-152